Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide
Authors/Creators
- 1. Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, San Manuel, Puebla, México. C. P. 72570
Description
ABSTRACT
Diabetic foot ulcers are clinical complications that affect to a 15-25% of patients of type-2 diabetes mellitus and are responsible for more hospitalizations than any other complication of diabetes. Authors of US2019070266 patent propose a method for treatment of diabetic foot ulcers. US2019070266 describes a method that consists of the administration of Liraglutide, at a dose of 1.2-1.8 mg, in patients with type 2 diabetes and with at least one risk factor for vascular disease, such as microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction and ankle/brachial index <0.9. The results of the clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration of Liraglutide.
Files
6 Liraglutide in diabetic foot ulcer US2019070266.pdf
Additional details
Identifiers
Related works
- Is identical to
- Journal article: https://repositorioinstitucional.buap.mx/handle/20.500.12371/9396 (URL)
References
- International Diabetes Federation (IDF) Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation; 2017.
- International Diabetes Federation (IDF) Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation; 2015.
- Pozo L, Bello F, Suarez A, et al. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World journal of diabetes, 2019, 10(5), 291-303.
- Zhang P, Lu J, Jing Y, et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Annals of medicine, 2017,49(2), 106-16.
- Whitehead M, Wickremasinghe S, Osborne A, et al. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert opinion on biological therapy, 2018,18(12), 1257-70.
- Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes research and clinical practice. 2018, 144:177- 191.
- Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World journal of diabetes, 2019,10(5), 269.
- Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. New England 1. Journal of Medicine, 2017;376(24):2367-75.
- Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. International journal of molecular sciences, 2016,17(6): 917.
- Ndip A, Jude EB. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. The international journal of lower extremity wounds, 2009,8(2): 82-94.
- Chastain CA, Klopfenstein N, Serezani CH, et al. A Clinical Review of Diabetic Foot Infections. Clinics in podiatric medicine and surgery, 2019,36(3), 381-395.
- Li H, Fu X, Zhang L, et al. Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. Journal of Surgical Research, 2008,145(1):41-8.
- Cheng B, Liu HW, Fu XB, et al. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. Journal of dermatological science, 2007,45(3):193-201.
- Yang Y, Xia T, Zhi W, et al. Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor. Biomaterials, 2011,32(18):4243-54.
- Morimoto N, Yoshimura K, Niimi M, et al. An exploratory clinical trial for combination wound therapy with a novel medical matrix and 1. fibroblast growth factor in patients with chronic skin ulcers: a study protocol. American journal of translational research, 2012,4(1):52- 9.
- Dong X, Xu J, Wang W, et al. Repair effect of diabetic ulcers with recombinant human epidermal growth factor loaded by sustained-release microspheres. Science in China Series C: Life Sciences, 2008,51(11):1039-44.
- Choi JS, Leong KW, Yoo HS. In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). Biomaterials, 2008,29(5):587-596.
- Eleftheriadou I, Tentolouris A, Tentolouris N, et al. Advancing pharmacotherapy for diabetic foot ulcers. Expert opinion on pharmacotherapy, 2019,20(9):1153-60.
- Laing T, Hanson R, Chan F, et al. Effect of pravastatin on experimental diabetic wound healing. Journal of Surgical Research, 2010,161(2):336-40.
- Bagheri M, Jahromi BM, Mirkhani H, et al. Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats. Journal of Surgical Research, 2011,169(1):e101-7.
- Babaei S, Bayat M, Nouruzian M, et al. Pentoxifylline improves cutaneous wound 1. healing in streptozotocin-induced diabetic rats. European journal of pharmacology, 2013,700(1-3):165-72.
- Soeren R, Novo Nordish, Belgium. Liraglutide in Diabetic Foot Ulcer. United States patent US2019070266. 2019 Mar 07.
- Xu X, Chen J, Hu L, et al. Liraglutide regulates the viability of pancreatic a-cells and pancreatic P—cells through cAMP-PKA signal pathway. Life sciences, 2018,195:87-94.
- Malm-Eijefalt M, Bj0rnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metabolism and Disposition, 2010,38(11), 1944-53.
- Flink JM, Larsen SM, Jensen SB, et al. Novo Nordisk. Belgium. Stable formulation of modified GLP-1. United States patent US8846618B2. 2014 Sep 30.
- Bisgaard LS, Bosteen MH, Fink LN, et al. Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/-mice. PLoS One, 2016;11(12), e0168396.
- Ao N, Yang J, Du J. Effect and mechanism of liraglutide on the apoptosis of human hepatocellular carcinoma HepG2 cells induced with palmitic acid. Zhonghua gan zang bing zazhi= Zhonghua ganzangbing zazhi= Chinese journal of hepatology, 2019;27(6):445-449.
- Kanda R, Hiraike H, Wada-Hiraike O, Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC cancer, 2018;18(1):657.
- Zhao W, Zhang X, Zhou Z, et al. Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Molecular Medicine Reports, 2018;17(4): 5202-5212.
- Dhatariya K, Bain SC, Buse JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial Diabetes Care 2018,41(10):2229-35.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 July 17. Identifier NCT01179048, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcom Results; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT011790 48.
- Tzanetakos C, Melidonis A, Verras C, et al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Services Research, 2014,4(1):419.
- Pedersen TB, Bonde C, Engelund DK, et al. Novo Nordisk. Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices. United States patent US20070010424. 2007 Jan 11.